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Abstract
Purpose
To evaluate the possible activity reduction in FDG-imaging in a Time-of-Flight (TOF) PET/
MR, based on cross-evaluation of patient-based NECR (noise equivalent count rate) mea-
surements in PET/CT, cross referencing with phantom-based NECR curves as well as initial
evaluation of TOF-PET/MR with reduced activity.
Materials and Methods
A total of 75 consecutive patients were evaluated in this study. PET/CT imaging was per-
formed on a PET/CT (time-of-flight (TOF) Discovery D 690 PET/CT). Initial PET/MR imag-
ing was performed on a newly available simultaneous TOF-PET/MR (Signa PET/MR). An
optimal NECR for diagnostic purposes was defined in clinical patients (NECRP) in PET/CT.
Subsequent optimal activity concentration at the acquisition time ([A]0) and target NECR
(NECRT) were obtained. These data were used to predict the theoretical FDG activity
requirement of the new TOF-PET/MR system. Twenty-five initial patients were acquired
with (retrospectively reconstructed) different imaging times equivalent for different activities
on the simultaneous PET/MR for the evaluation of clinically realistic FDG-activities.
Results
The obtained values for NECRP, [A]0 and NECRT were 114.6 (± 14.2) kcps (Kilocounts per
second), 4.0 (± 0.7) kBq/mL and 45 kcps, respectively. Evaluating the NECRT together with
the phantom curve of the TOF-PET/MR device, the theoretical optimal activity concentration
was found to be approximately 1.3 kBq/mL, which represents 35% of the activity concentra-
tion required by the TOF-PET/CT. Initial evaluation on patients in the simultaneous TOF-
PET/MR shows clinically realistic activities of 1.8 kBq/mL, which represent 44% of the
required activity.
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Conclusion
The new TOF-PET/MR device requires significantly less activity to generate PET-images
with good-to-excellent image quality, due to improvements in detector geometry and detec-
tor technologies. The theoretically achievable dose reduction accounts for up to 65% but
cannot be fully translated into clinical routine based on the coils within the FOV and MR-
sequences applied at the same time. The clinically realistic reduction in activity is slightly
more than 50%. Further studies in a larger number of patients are needed to confirm our
findings.
Introduction
Positron emission tomography/magnetic resonance (PET/MR) using 18-Fluoro-deoxyglucose
(FDG) opens potentially new perspectives in the field of clinical molecular imaging. Combin-
ing the high soft tissue contrast of MR, functional image procedures of MR and the molecular
ability of PET may improve the anatomical correlation and provide more clinically relevant
information [1]. As a new imaging modality, it is hoped that PET/MR shows some significant
advantages over PET/Computed tomography (CT) e.g. in head and neck cancer evaluation
[2,3] or liver metastases detection [4]. Besides the potential of improved lesion characterisation,
one expected benefit is the reduction of radiation exposure by omitting the CT–based dose and
also reducing the FDG- activity requirement[5]. Such a reduction in activity in the PET-com-
ponent of the evaluated TOF-PET/MR system can be achieved e.g. with a combination of sili-
con-based detector technology and larger solid angle coverage [6,7].
The noise-equivalent count rate (NECR) represents an objective measurement of PET-sys-
tem performance that reflects the ratio of true events to the overall detected events, which
include randoms and scatters [8]. It is calculated following the National Electrical Manufactur-
ers Association (NEMA) recommendations, using a 20-cm-diameter and 70-cm-long cylinder
that is assumed to provide a reasonable characterization of whole-body image quality [9].
The noise equivalent count rate is the standard metric for PET scanner performance pro-
vided by the manufacturers and determined as part of acceptance testing for new equipment
[10].
However, obtaining the NECR values from phantoms does not entirely reflect clinical rou-
tine behavior in patients since this measurement simply does not account for variations in the
fractions of the scatter and random events that are internal to the patient [11].
In a pre-evaluation to this presented study, it was shown that NECR measured in patients
can predict clinically perceived image quality in PET-imaging and a corresponding FDG-activ-
ity threshold above which the acquired PET images have good-to-excellent perceived quality in
more than 90% of patients [12].
Using these data as the basis of the present study, we use the NECR measured in patients in
PET/CT to predict the theoretically achievable FDG-activities in a new whole-body TOF-PET/
MR, based on the NECR curves measured in a standard NEMA phantom.
The aim of the study was (1) to investigate the amount of theoretically possible dose reduc-
tion in a new TOF-PET/MR compared to standard TOF-PET/CT by comparison of NECR-
measurements in patients (in PET/CT) and NECR measured in phantoms (PET/MR) and (2)
to evaluate the clinically realistic reduction in activity in PET/MR by evaluation of different
(retrospectively reconstructed) imaging times which are equivalent to different FDG-activities.
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Materials and Methods
Patient population
A total of 75 consecutive patients (81 exams) were evaluated retrospectively. All patients were
referred for a clinical FDG-PET/CT from January to December/2012 and underwent a PET/
CT-MR using a tri-modality setup. Based on the retrospective nature of the study, no formal
institutional ethics committee approval was needed and a waiver was provided.
Exclusion criteria applied were uncontrolled glucose levels and patients who did not fast for
a minimum of 4 hours prior to the examination, unwillingness to undergo the additional MR
examination, claustrophobia, MR-incompatible medical devices (e.g. cardiac pacemaker, insu-
lin pump, neurostimulator, cochlear implant). Another exclusion criterion was presence of
artefacts in at least one bed-position, which made clinical reading not applicable. Parts of the
evaluated patient population were also evaluated within the context of another study which is
currently under review as well.
PET/CT imaging
PET/CT imaging was performed on a PET/CT-MR setup including a time-of-flight Discovery
690 PET/CT and a Discovery 750w 3T MR (both GE Healthcare, Waukesha, WI).
PET/CT was performed according to the EANM procedure guidelines for tumour PET
imaging [13]. Patients fasted for at least 4 hours prior to injection of 18F-fluorodeoxyglucose
(FDG). The mean FDG injected activity was 311.7 MBq (SD = 21.3 MBq, range 231.1–373.4
MBq). The mean FDG injected activity/body weight was 4.3 MBq/kg (SD = 0.9 MBq/kg, range
2.6–6.6 MBq/kg).
Unenhanced low-dose CT and PET emission data were acquired from the mid-thigh to the
vertex of the skull. CT data were acquired in shallow-breathing with dose modulation between
15–80 mA, 120 kVp and a pitch of 0.984:1, reconstructed to images of 0.98 mm transverse
pixel size and 3.75 mm slice thickness. PET data was acquired in 3D time-of-flight mode with
scan duration of 2 min per bed position, an axial FOV of 153 mm and a 23% overlap of bed
positions, resulting in a total PET acquisition time ranging from 16 to 20 minutes. The emis-
sion data were corrected for randoms, dead time, scatter and attenuation and iteratively recon-
structed (OSEM, 3 iterations, 18 subsets)[3].
Image processing and analysis
The acquired PET and CT images were transmitted to a dedicated review workstation (Advan-
tage Workstation, GE Healthcare), which enables the review of the PET and CT images side by
side or in fused/overlay mode (PET/CT).
In a first step, all data were automatically analysed using Matlab (MathWorks, Natick, MA,
USA) to estimate the noise-equivalent count rate (NECR) versus activity concentration in a
similar manner to the National Electrical Manufacturers Association (NEMA) analysis, includ-
ing scatter or attenuation correction methods applied to patient data and how scatter and ran-
doms were estimated, based on previous publications [11,14–17]. This measurement is
essentially the same usually performed on phantom data, but the required data (the number of
true, scattered and random counts) are estimations either provided by the scanner software or
automatically extracted from the reconstructed image. Methods how to evaluate NECR mea-
surements in patients have been described before by different authors [8,11,15]. To highlight
the fact that these NECR values were measured on patient data, we indicate this as NECRP.
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In a second step, all the PET/CT exams were read by a board-certified nuclear medicine
physician / radiologist and by a radiologist with substantial experience in PET/CT image
reading.
One subjective score was defined to evaluate image quality. The IQ local score (IQL) was a
three-point scale assigned to each bed position in axial plane in all patients (n = 655 bed posi-
tions), where 1 means poor, 2 means good and 3 means excellent IQ. In general, smoothness
and sharpness of the images have been considered for the evaluation. The liver homogeneity
and graininess and the contrast between different structures that accumulate different levels of
tracer, like the lung and chest wall, were analysed.
Patient data were analysed concerning overall weight, body mass index (BMI) and FDG-
activity at the start of acquisition (DAcq). One additional parameter was defined for each
patient: the ratio between DAcq and patient weight (RDW).
The RDW threshold was determined, above which the resulting image quality was at least
“good” (IQL> 2) in more than 90% of patients. The rationale for choosing RDW as the thresh-
old parameter is that this measurement is routinely used to calculate patient’s dose, according
to EANM guidelines, making it more reproducible. Using the RDW threshold, the optimal
NECRP for diagnostic purposes was defined based on the RDW x NECRP curve (Fig 1).
The NECRP was then cross-referenced in the graphic NECRP x Activity concentration
(Fig 2) in order to get the corresponding optimal activity concentration at the acquisition time
([A]0). By obtaining this value, it is now possible to establish the relation between patient-
based and phantom-based count-rate measurements. Applying the calculated [A]0 value on
the NEMA phantom curve of the GE Discovery D690 (Fig 3) that was used in these acquisi-
tions, the target NECR (NECRT) was obtained. Notice that this image quality target value is
independent of the PET system used.
Using this NECRT, it is therefore possible to estimate, for any PET system, the activity con-
centration required to obtain the desired image quality (e. g. good-to-excellent”) in a given per-
centage of patients ([A]N), by cross-evaluation with the NECR curves of the system compared.
Fig 1. Relation between RDW and RBMI and clinical NECRmeasured in patients (NECRP).
doi:10.1371/journal.pone.0128842.g001
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In a pre-evaluation a threshold in which 90% of cases were rated with “good to excellent”
image quality was defined [12].
In the presented study, this procedure was performed for the particular case of a new
whole-body TOF-PET/MR device in order to predict the injected FDG- activity needed to
Fig 2. Relation between NECRmeasured in patients and activity concentration.
doi:10.1371/journal.pone.0128842.g002
Fig 3. The NEMA phantom curve of the TOF-PET/CT (continuous) and TOF-PET/MR (dashed), provided by its manufacturer. See enlarged image of
the clinically relevant area (black box) in Fig 4.
doi:10.1371/journal.pone.0128842.g003
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provide good-to-excellent images, which is expected to be significant lower. The GE Signa
PET/MR is a whole-body scanner combining a 3T wide-bore MR system with a 25 cm PET
detector ring based on SiPM technology and mounted on a customized radiofrequency coil.
Furthermore to transfer our results not only technically but also clinically, the first 25
patients on the new simultaneous TOF-PET/MR were evaluated as well. For this purpose,
(acquired 2 min/bed in PET/CT and 4 min/bed in simultaneous TOF-PET/MR) patient-data
was reconstructed retrospectively to expose both systems to the same amount of emitted
counts. Reconstructed acquisition times were adjusted for tracer decay between the
acquisitions.
The acquisition times were reconstructed to be similar by unlisting the list mode data and
creating similar sinograms to be compared for each acquisition time. This way, the two result-
ing sinograms are representing an equivalent of the same injected 18F-FDG acitivity. After
reducing PET/MR acquisition times to match the PET/CT decay integral, the average was
196 ± 25 seconds/bed.
Our next step was to reduce both, PET/CT and PET/MR acquisition times in pre-defined
steps to evaluate at which time point the PET/CT and/or the PET/MR image were considered
not “good to excellent” anymore. For these whole body scans, we un-listed the emission data
for 120, 100, 80, 60, 40 and 30 seconds/bed for PET/CT; the corresponding equivalent times
for PET/MR were 206, 170, 134, 98, 68, 53 ± 25 seconds/bed. By defining this threshold, and
again applying the calculated value on the NEMA phantom curve of the simultaneous PET/
MR system, it is possible to extrapolate not only a theoretical “technical” threshold for activity
reduction but also a clinically validated threshold.
Statistical Analysis
All statistical tests were performed using SPSS Statistics Version 21 (IBM, Armonk, NY, USA).
P-values< 0.05 were considered statistically significant. Pearson’s correlation analysis was per-
formed to evaluate the relation between NECR, and RDW.
Results
The RDW was significantly correlated with NECRP (r = 0.89, p-value< 0.01), as presented on
Fig 1. The threshold at scan time calculated for RDW was 2.6 MBq/kg.
The obtained values for NECRP, [A]0 and NECRT were 114.6 (± 14.2) kcps, 4.0 (± 0.7) kBq/
mL and 45 kcps, respectively. Cross-referencing this NECRT to the phantom curve of the new
TOF-PET/MR system (Fig 3), the corresponding activity concentration at scan time was found
to be approximately 1.4 kBq/mL. At this activity concentration, 90% of images would be rated
with “good to excellent” image quality.
Thus, the theoretical activity concentration required by the new TOF- PET/MR is 35% of
the activity concentration required by the TOF- PET/CT. The corresponding ideal activity
threshold at the injection time is 1.3 MBq/kg.
With the same method it is possible to calculate and find any required clinical image quality
threshold as well as the required threshold for the injected activity for any system for which the
NECR curve is available. Considering 3.8 MBq/kg as the optimal threshold at injection time for
the compared TOF-PET/CT, which requires an activity concentration of 4.0 kBq/mL, the opti-
mal threshold could be calculated with TO = 0.95 x [A]N, where the [A]N is the activity concen-
tration value for which the corresponding NECR is 45 kcps in the NECR curve.
Since these values are representing the theoretically possible reduction in injected activity,
the evaluation on the simultaneously acquired PET/MRI showed slightly different results.
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Here, on average the PET/MR image was rated not “good to excellent” anymore at a time point
equivalent to 1.8 kBq/mL which represents 44% of the initially required activity (Fig 4).
Discussion
This study is an extension of a previous study about clinical image quality perception and cor-
responding NECR measurements in PET systems. The results of this pre-evaluation indicated
that findings based on the NECRP metric could be rescaled and applied for different PET sys-
tems [8,11,15,18]. Other groups have evaluated methods about NECR measurements in
patients and corresponding image quality as well [8,19,20]. In the presented study, to the best
of our knowledge, we are the first to present the extrapolation of clinically evaluated image
quality and corresponding NECR measurements in patients from PET/CT to a new TOF-PET/
Fig 4. Evaluation and transfer steps from activities in PET/CT (1) to theoretically (2,3) achievable reduction in injected activity in TOF-PET/MR (4)
and clinically realistically activities in TOF-PET/MR (5—blue arrow).
doi:10.1371/journal.pone.0128842.g004
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MR (SIGNA PET/MR, GE Healthcare, Waukesha, MI, USA). Our results show that with this
new system, a theoretical reduction in injected activity down to nearly one third of 18F-FDG,
and a clinically realistic reduction of slightly more than 50% in FDG-activity compared to a
TOF-PET/CT is possible.
Much effort has been put into optimization of the injected FDG-activity and maintaining
image quality at the same time. Ideally, FDG-activity should be kept as low as possible consid-
ering the cost of the tracer and the radiation exposure for the patient and staff [21]. Patient
morphology, the time acquisition per bed position and the used PET reconstruction (e.g. 2D
vs. 3D, time of flight) are some of the parameters that have been shown to influence the FDG-
dosing requirements [11,16,21].
However, regardless all of these parameters, the performance of every PET scanner is intrin-
sically (and non-linearly) dependent on the amount of injected activity. Although there is a
debate on how to derive NECR values, the measurements following the NEMA protocol repre-
sent one of the most accepted and widely used way of showing the relation between the activity
and acquired data quality. The controversial issue concerning the use of NECR is the difficulty
to extrapolate the phantom-based measurements to patient acquisitions, since the response in
humans can be quite variable [11]. The use of NECR nevertheless appears as a potential tool to
standardize the FDG activity needed to get images in diagnostic quality. One possibility is to
measure the NECR directly in clinical patients, which has already been done in other studies
[8,11].
Recently, McDermott et. al have shown that the noise equivalent counts per axial length was
also an effective and objective indicator of patient image quality, being able to discriminate
images of good/excellent quality from those of poorer image quality with higher degree of accu-
racy than noise equivalent count density and liver signal to noise ratio [22].
Another challenge of correlating the NECR measured in patients to the visually perceived
PET-image quality assessed by imaging specialists. Previous studies have compared the NECR
phantom-based to visual image quality [17,19] or NECR measured in patients to signal-to-
noise as a parameter of image quality [8,11].
As an initial step, our study compared the NECR measured in patients and visual image
quality assessed by nuclear medicine physicians/radiologists, favouring the clinical reliability of
our findings compared to other available studies that were not assessed by imaging specialists.
In a second step, the newly available TOF-PET/MR has been evaluated using the NEMA
recommendations. A NECR curve (phantom based) has been created and was used to estimate
the theoretically required activity concentration in order to achieve again good-to-excellent
images. In the last step these results were then evaluated and transferred to the simultaneously
acquired PET/MR images to evaluate the clinically realistic reduction in injected activity.
Our findings suggest that the optimal activity concentration required in the PET/MR is 35%
(a reduction of 65%) of the activity concentration required by the comparatively used TOF-
PET/CT. There are several technical reasons and explanations for this.
Delso et. al have already suggested that the integrated PET/MR features could require lower
activities[5]. For a non-TOF whole-Body PET/MR used by Delso et al., a longer axial FOV and
reduced detector ring diameter lead to higher count rates and an increased sensitivity, both in
stand-alone operation and with simultaneous MR image acquisition. Thus, such a PET/MR
system reaches its saturation and dead-time points with lower activities[5].
The evaluated TOF-PET/MR system has an increased axial field of view (FOV) compared
to the TOF-PET/CT, too. Thus, the increased axial FOV increases sensitivity at the scanner
center in a d2 (axial field of view) relationship. For example, going from 15 to 25cm axial FOV
leads to (25/15)2, which is a 2.78 factor improvement.
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Another feature of the evaluated system scanner is the diameter compared to standard PET/
CT, which also provides an approximately linear gain in sensitivity. For example here, going
from 810 mm to 622 mm diameter leads to (810/622) a factor of 1.3 of improvement. The eval-
uated PET/MR has a detector face-to-face diameter of 62 cm and an axial FOV of 25 cm in
PET.
Concerning detector configuration, the new PET system employs five rings of 112 detector
blocks where the scintillator crystals are coupled to 1 x 3 arrays of SiPM devices. The SiPM
itself has several advantages compared with conventional detector materials, e.g. timing resolu-
tion, gain and corresponding noise [23,24].
The PET detectors modules are mounted on the outside of a novel radiofrequency (RF)
body coil that provides additional space to accommodate the PET detector ring with a 60 cm
patient bore. This design also reduces the amount of PET-attenuating material in the PET field
of view, contributing in part to the reduced activity requirements. The use of scatter recovery
techniques additionally supports this advantage as well [25].
A recent study has evaluated the advantage of the implementation of such recovery proce-
dures by using the inter-block Compton scatter on TOF-PET scanners. It was found that this
setup is expected to result in an overall scanner sensitivity improvement of up to 20% without
significant processing overhead [25].
Summing up all these newly embedded technologies in the evaluated TOF-PET/MR, the
analysed system has the potential to require significantly less activity while preserving diagnos-
tic image quality.
However, there are also several reasons to consider why those improvements in dosage are
not fully translated into clinical routine. To make full use of the system’s capabilities, the full
field-of-view has to be used to achieve the full sensitivity. This is obviously not possible for
brain imaging where the “natural” field-of-view is shorter.
Furthermore, one has to account for the MR-coils within the PET-FOV, which causes a
decrease in counts as well. This is especially important for brain imaging, because the head/
neck coils are a fully surrounding cage, while surface coils for body imaging are made of less
material and are more flexible [26–29]. Thus, in cases of brain imaging, one might loose up to
15–20% of sensitivity in the center of the image based on the head and neck coil. Surface coils
however, account for a smaller amount of sensitivity loss [30].
Lastly, the execution of MR-sequences are known to decrease the performance of PET-sys-
tems, too, however, largely not clinically significant (< 5%) [31]. Summing up these additional
considerations, an activity reduction of up to 65% (or using just 35% of the activity compared
to current TOF-PET/CT) is a theoretical number, but clinical reality as initially evaluated here
also shows roughly a reduction in injected activity of> 50%.
One limitation is certainly that we only evaluated the first initial patients on the simulta-
neous PET/MR to test the clinical transferability of our results.
Furthermore, clinical image perception is always prone to a certain extent of subjectivity of
the readers; clinical image perception in PET/MRI might be different compared to PET/CT.
Conclusion
The new TOF-PET/MR device requires significantly less activity to generate PET-images with
good-to-excellent image quality, due to improvements in detector geometry and detector tech-
nologies. The theoretical achievable reduction of 18F-FDG acitivity was proven based on cross-
evaluation of clinical images quality in PET/CT and phantom based NECR measurements in
TOF-PET/MRI. Further studies in a larger number of patients are needed to confirm our
findings.
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